Opinion

Video

Evaluating CDK4/6 Inhibitor Safety Profiles: An Analysis of Adverse Events

A medical expert compares CDK4/6 inhibitors and discusses the importance of monitoring specific parameters, such as ECGs and laboratory tests, to minimize adverse events associated with each drug.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
1 KOL is featured in this series.
1 expert in this video
1 expert in this video
Related Content
HRT Hormone Therapy sign surrounded by plants and hormone therapy pills | Image Credit: © tilialucida - stock.adobe.com
July 2nd 2025

Study Links Specific Hormone Therapies to Breast Cancer Risk in Younger Women

Alexandra Gerlach, Associate Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Chemotherapy IV drip -- Image credit: sweetlemontea | stock.adobe.com
June 4th 2025

ASCO 2025: Adding Carboplatin Did Not Result in Statistically Significant Improvements in Patients With TNBC

Gillian McGovern, Associate Editor
Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations
April 29th 2025

Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations

Alexandra Gerlach, Associate Editor
Antibodies attacking cancer cell | Image Credit: © Anusorn - stock.adobe.com
June 2nd 2025

ASCO 2025: Expert Insights on Endocrine, Cardiac, Ocular, and Dermatologic Toxicities in Breast Cancer Care

Alexandra Gerlach, Associate Editor
3D visualization of breast cancer on transparent body | Image Credit: © Crystal light - stock.adobe.com
May 30th 2025

ESR1, PIK3CA, and Beyond: Precision Therapy Advances in HR+ Breast Cancer

Alexandra Gerlach, Associate Editor